APTX News and Press, Aptinyx Inc. From 01/31/23

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SV...

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52 nd Annual Meeting of the Society for Neuroscience being held No...

Aptinyx Inc. (APTX) Q3 2022 Earnings Conference Call November 08, 2022 05:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO Ashish Khanna - CFO and CBO Kathryn King - SVP, Clinical and ...

Aptinyx press release ( NASDAQ: APTX ): Q3 GAAP EPS of -$0.23 beats by $0.01 . Cash Position: Cash and cash equivalents were $66.5 million as of September 30, 2022, compared to $106.1 million as of December 31, 2021. Net Loss: Net loss was $15.3 million for the t...

Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables...

NIH HEAL Initiative grant, administered by NIDA, funds preclinical and clinical studies of NYX-783 in opioid use disorder Preclinical studies demonstrate NYX-783 has promising activity and safety profile relevant to treatment of opioid use disorder, clearing path for fundi...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET...

Results from the Phase 2 study are expected in 1Q 2023 Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 99 pati...

Cowen downgraded Aptinyx Inc. ( NASDAQ: APTX ) to Market Perform from Outperform after the clinical-stage biotech announced on Monday that its Phase 2b trial for oral candidate NYX-2925 did not reach the primary goal of pain reduction compared to placebo. “We await ...

Aptinyx ( NASDAQ: APTX ) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial. The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in...